Clinical Trials
5 trialsNCT01905813 2026-05-11
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Incyte Corporation
Phase 1 Completed
NCT03755414 2025-04-06
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
Phase 1 Completed
NCT03989466 2024-10-10
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02018861 2023-09-28
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Incyte Corporation
Phase 1/2 Completed
NCT02760485 2023-06-15
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Incyte Corporation
Phase 1/2 Completed